CDK

Cat. No.

A54300

CAS No.

1627696-52-9

(S)-LY3177833

(S)-LY3177833 is a potent inhibitor of Cdc7 kinase, known for its oral bioavailability. This compound exhibits significant in vitro anticancer activity, making it a valuable tool for cancer research. Researchers can employ (S)-LY3177833 to explore the mechanisms of Cdc7 inhibition and its potential therapeutic applications in oncology.

Cat. No.

A54301

CAS No.

883027-32-5

DSS30

DSS30 is a selective inhibitor of P25/CDK5, targeting the phosphorylation of amyloid precursor protein lyase 1 (BACEl). By inhibiting this phosphorylation, DSS30 effectively reduces the secretion of β-amyloid (Aβ), a key factor in the pathogenesis of Alzheimer's disease. This compound is valuable for research into neurodegenerative disorders and mechanisms underlying Aβ accumulation.

Cat. No.

A54303

CAS No.

451458-32-5

CDK8-IN-17

CDK8-IN-17 is a potent inhibitor of cyclin-dependent kinase 8 (CDK8) with an IC50 value of 9 nM. This compound regulates transcriptional control and has demonstrated significant potential in cancer research by modulating oncogenic pathways. CDK8-IN-17 is valuable for studies investigating the role of CDK8 in tumorigenesis and therapeutic applications targeting cellular proliferation.

Cat. No.

A54304

CAS No.

2991074-93-0

CDK9-IN-31

CDK9-IN-31 is a selective inhibitor of cyclin-dependent kinase 9 (CDK9), which plays a critical role in regulating transcription and cell proliferation. By inhibiting CDK9, this compound demonstrates significant anti-cancer activity through the suppression of cancer cell growth. Its potential applications extend to cancer research, providing valuable insights into therapeutic strategies targeting transcriptional regulation in malignancies.

Cat. No.

A54305

CAS No.

2762181-73-5

CDK/HDAC-IN-1

CDK/HDAC-IN-1 is a potent inhibitor targeting cyclin-dependent kinases CDK2, CDK4, CDK6, and histone deacetylase 6 (HDAC6) with respective IC50 values of 60.9 ± 2.9 nM, 276 ± 22.3 nM, 27.2 ± 4.2 nM, and 128.6 ± 0.4 nM. This dual-action compound demonstrates significant biological activity in inhibiting cell cycle progression and modulating gene expression. CDK/HDAC-IN-1 is suitable for research applications exploring cancer biology, epigenetic regulation, and therapeutic strategies targeting CDK and HDAC pathways.

Cat. No.

A54306

CAS No.

2588110-62-5

CDK7-IN-10

CDK7-IN-10 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7), with an IC50 value of less than 100 nM. This compound effectively inhibits kinase activity, leading to reduced cell proliferation and the induction of apoptosis in various cell types. CDK7-IN-10 is valuable for research applications focused on cancer biology and therapeutic development targeting cell cycle regulation.

Cat. No.

A54307

CAS No.

2773402-44-9

CDK9-IN-38

CDK9-IN-38 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), exhibiting IC50 values of 1.2 nM for the wild-type enzyme and 3.3 nM for the L156F mutant variant. This compound has demonstrated significant inhibitory effects on tumor growth in both in vitro and in vivo models. CDK9-IN-38 is a valuable tool for research into the regulation of transcriptional control and the therapeutic potential for cancer treatment.

Cat. No.

A54309

CAS No.

2649120-20-5

CDK4/6-IN-7

CDK4/6-IN-7 is a potent and selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), with IC50 values of 1.58 nM and 4.09 nM, respectively. This orally active compound demonstrates significant biological activity, making it a valuable tool for investigating the role of CDK4/6 in various cancer models, particularly in breast cancer research. Its specificity and efficacy support studies aimed at understanding and targeting cell cycle progression in tumor cells.

Cat. No.

A54311

CAS No.

1244027-03-9

Cdc7-IN-15

Cdc7-IN-15 is a selective inhibitor of Cdc7 kinase, a crucial regulator of the cell cycle. This compound exhibits significant anti-proliferative activity, making it a valuable tool for cancer research. It is particularly useful for studies investigating the role of Cdc7 in tumorigenesis and as a potential therapeutic target in cancer treatment.

Cat. No.

A54312

CAS No.

2516247-98-4

PF-06842874

PF-06842874 is a selective inhibitor of CDK4 and CDK6, targeting the cyclin D1 and cyclin D3 complexes with Ki values of 62 nM and 130 nM, respectively. This compound demonstrates significant biological activity in the inhibition of cell proliferation, making it a valuable tool in cancer research and the study of pulmonary arterial hypertension. Its ability to modulate cell cycle progression positions PF-06842874 as an important reagent for investigating therapeutic strategies in oncological and vascular disease contexts.

Cat. No.

A54313

CAS No.

2055741-42-7

CDK7-IN-32

CDK7-IN-32 is a potent inhibitor of Cyclin-dependent kinase 7 (CDK7), a key regulator of cell cycle progression and transcriptional regulation. This compound effectively disrupts CDK7 activity, leading to decreased phosphorylation of its substrates and subsequent modulation of cellular proliferation and survival. CDK7-IN-32 is utilized in cancer research and studies investigating the role of CDK7 in transcriptional control and therapeutic resistance.

Cat. No.

A54314

CAS No.

3020773-81-0

CDK9-IN-28

CDK9-IN-28 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), which plays a critical role in regulating transcription and cell cycle progression. This compound exhibits strong anti-proliferative effects, particularly in solid tumor models, making it valuable for cancer research. Additionally, CDK9-IN-28 serves as a target protein ligand for the synthesis of PROTACs, aiding in the development of innovative therapeutic strategies for targeting CDK9-dependent pathways.

Cat. No.

A54315

CAS No.

844441-29-8

LZ9

LZ9 is an ATP-competitive inhibitor of CDK1 and CDK2. This compound demonstrates significant biological activity in inhibiting cyclin-dependent kinases, making it a valuable tool for investigating cell cycle regulation. LZ9 has potential applications in research focused on colorectal cancer (CRC), aiding in the exploration of therapeutic strategies targeting this malignancy.

Cat. No.

A54317

CAS No.

2987897-39-0

CDK9-IN-49

CDK9-IN-49 is a potent inhibitor of Cyclin-dependent kinase 9 (CDK9) with an IC50 of 7.32 nM. This compound effectively suppresses the proliferation of various cancer cell lines, making it a valuable tool for cancer research. CDK9-IN-49 is particularly relevant for studies focused on acute myeloid leukemia and prostate cancer, facilitating investigations into therapeutic strategies targeting CDK9 pathways.

Cat. No.

A54318

CAS No.

2662813-96-7

CDK4/6-IN-24

CDK4/6-IN-24 is a potent inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), key regulators of the cell cycle. This compound demonstrates broad-spectrum antitumor activity across various cancer cell lines, with IC50 values in the submicromolar range. CDK4/6-IN-24 is a valuable tool for researchers investigating cell cycle regulation and therapeutic strategies for cancer treatment.

Cat. No.

A54319

CAS No.

3106928-15-5

CDK2-IN-54

CDK2-IN-54 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), a critical regulator of the cell cycle. This compound demonstrates potent anti-proliferative activity in various cancer types, including triple-negative breast cancer, ovarian cancer, bladder cancer, and uterine cancer. CDK2-IN-54 is valuable for research applications focused on understanding cell cycle dynamics and exploring therapeutic strategies in oncology.

Cat. No.

A54320

CAS No.

3039540-19-4

PROTAC CDK9 degrader-11

PROTAC CDK9 degrader-11 is an orally active PROTAC degrader that specifically targets CDK9, demonstrating a DC50 value of 1.09 nM. This compound shows cytotoxicity in various small cell lung cancer cell lines with an IC50 in the nanomolar range. PROTAC CDK9 degrader-11 effectively induces cell cycle arrest at the G0/G1 phase and reduces invasion in DMS114 and DMS53 cells. Additionally, it exhibits significant antitumor efficacy in NCI-H446 xenograft mouse models, making it a valuable tool for cancer research and therapeutic development.

Cat. No.

A54321

CAS No.

2765997-88-2

CDK4/6-IN-21 maleate

CDK4/6-IN-21 maleate is a potent inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), exhibiting IC50 values of 3.88 nM and 3.31 nM against CDK4 and CDK6, respectively. This compound demonstrates significant antitumor activity, making it a valuable tool for research into cell cycle regulation and cancer therapeutics. Its targeted inhibition of CDK4/6 positions it as a key reagent for studying oncogenic pathways and developing new cancer treatment strategies.

Cat. No.

A54322

CAS No.

3033950-84-1

CDK4/6-IN-20

CDK4/6-IN-20 is a potent inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/CDK6), demonstrating IC50 values of 1.9 nM and 14.2 nM, respectively. This compound effectively inhibits cell proliferation, making it a valuable tool for cancer research applications. Its selective inhibition of CDK4/6 contributes to understanding cell cycle regulation and potential therapeutic interventions in malignancies.

Cat. No.

A54324

CAS No.

1229665-91-1

CGP-79807

CGP-79807 is a purine-based inhibitor targeting cyclin-dependent kinases (CDKs). It effectively disrupts the cell cycle by inhibiting CDK activity, leading to the suppression of tumor cell proliferation. This compound is valuable in cancer research for exploring the mechanisms of cell cycle regulation and potential therapeutic strategies.

Cat. No.

A54325

CAS No.

2803837-13-8

CDK2/4/6-IN-1

CDK2/4/6-IN-1 is a potent inhibitor of cyclin-dependent kinases 2, 4, and 6, with IC50 values of 2.5 nM, 23.7 nM, and 44.3 nM, respectively. This compound is valuable for cancer research, allowing for the study of cell cycle regulation and tumor progression. Additionally, CDK2/4/6-IN-1 features an alkyne group enabling its use in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions, facilitating bioconjugation and labeling applications in chemical biology.

Cat. No.

A54326

CAS No.

1670273-47-8

[pThr3]-CDK5 Substrate

[pThr3]-CDK5 Substrate is a specific substrate for cyclin-dependent kinase 5 (CDK5), functioning primarily through phosphorylation at threonine 3. This substrate is based on the histone H1 peptide sequence, which effectively binds within the active site of CDK5. It is phosphorylated by CDK5 with a Km value of 6 µM, making it useful for studies examining CDK5 activity and regulation in various biological contexts.

Cat. No.

A54327

CAS No.

2173190-60-6

CDK7-IN-22

CDK7-IN-22 is a selective inhibitor of cyclin-dependent kinase 7 (CDK7) with demonstrated antitumor activity. Its inhibition of CDK7 plays a crucial role in modulating transcriptional regulation and cell cycle progression, making it a valuable tool for cancer research. CDK7-IN-22 is suitable for studies on tumorigenesis, therapeutic resistance, and cellular proliferation pathways.

Cat. No.

A54328

CAS No.

2765676-49-9

CDK7-IN-14

CDK7-IN-14 is a selective inhibitor of cyclin-dependent kinase 7 (CDK7), a key enzyme involved in transcriptional regulation and cell cycle progression. This pyrimidinyl derivative exhibits significant potential in cancer research, particularly in the study of tumors characterized by transcriptional dysregulation. CDK7-IN-14 may serve as a valuable tool for investigating therapeutic strategies targeting CDK7 in various malignancies.

Cat. No.

A54329

CAS No.

1414943-94-4

(+)-Atuveciclib ((+)-BAY-1143572, d-BAY-1143572)

Synonyms: (+)-BAY-1143572; d-BAY-1143572

(+)-Atuveciclib is a selective inhibitor of cyclin-dependent kinase 9 (CDK9) and the positive transcription elongation factor b (P-TEFb). With an IC50 value of 13 nM, it effectively suppresses CDK9 in cellular assays. This compound is primarily utilized in research related to transcription regulation and cancer therapeutics, offering insights into CDK9-mediated pathways and their role in various malignancies.